{"date":"2025-08-18","count":15,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-7837-2025-08-18-1744-1t9wtuz","company_id":"7837","company":"啟新生","market":"興櫃","industry":"生技醫療","date":"2025-08-18","time":"17:44:55","subject":"公告本公司受邀參加證券櫃檯買賣中心舉辦「興櫃公司業績說明會」","clause":"第30款","fact_date":"2025-08-19","cite_as":"公開資訊觀測站重大訊息：啟新生（7837），2025-08-18 17:44，「公告本公司受邀參加證券櫃檯買賣中心舉辦「興櫃公司業績說明會」」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-08-18-1742-12lnrwj","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-08-18","time":"17:42:18","subject":"本公司使用於治療惡性肺間皮癌生物製劑Pegargiminase(ADI-PEG 20)之上市查驗登記申請(BLA)正式進入美國FDA藥證審查階段","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-08-18 17:42，「本公司使用於治療惡性肺間皮癌生物製劑Pegargiminase(ADI-PEG 20)之上市查驗登記申請(BLA)正式進」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7729-2025-08-18-1733-m1lgr6","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2025-08-18","time":"17:33:53","subject":"公告本公司經主管機關核准調整114年第一次現金增資發行價格","clause":"第44款","fact_date":"2025-08-18","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2025-08-18 17:33，「公告本公司經主管機關核准調整114年第一次現金增資發行價格」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2025-08-18-1731-u9hynx","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2025-08-18","time":"17:31:15","subject":"公告本公司114年第一次現金增資認股基準日暨相關事宜(補充發行價格)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2025-08-18 17:31，「公告本公司114年第一次現金增資認股基準日暨相關事宜(補充發行價格)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3716-2025-08-18-1701-ut6y8s","company_id":"3716","company":"中化控股","market":"上市","industry":"生技醫療","date":"2025-08-18","time":"17:01:49","subject":"代子公司「中國化學製藥股份有限公司」及「中化裕民健康事業股份有限公司」公告主辦會計異動","clause":"第8款","fact_date":"2025-08-18","cite_as":"公開資訊觀測站重大訊息：中化控股（3716），2025-08-18 17:01，「代子公司「中國化學製藥股份有限公司」及「中化裕民健康事業股份有限公司」公告主辦會計異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3716-2025-08-18-1701-l7qirp","company_id":"3716","company":"中化控股","market":"上市","industry":"生技醫療","date":"2025-08-18","time":"17:01:11","subject":"公告本公司會計主管異動","clause":"第8款","fact_date":"2025-08-18","cite_as":"公開資訊觀測站重大訊息：中化控股（3716），2025-08-18 17:01，「公告本公司會計主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6617-2025-08-18-1636-1otu61u","company_id":"6617","company":"共信-KY","market":"上櫃","industry":"生技醫療","date":"2025-08-18","time":"16:36:22","subject":"公告114年第2季財務報告董事會預計召開日期為114年8月26日","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：共信-KY（6617），2025-08-18 16:36，「公告114年第2季財務報告董事會預計召開日期為114年8月26日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6762-2025-08-18-1616-1m9ssep","company_id":"6762","company":"達亞","market":"上櫃","industry":"生技醫療","date":"2025-08-18","time":"16:16:43","subject":"本公司董事長決定限制員工權利新股之增資基準日","clause":"第53款","fact_date":"2025-08-18","cite_as":"公開資訊觀測站重大訊息：達亞（6762），2025-08-18 16:16，「本公司董事長決定限制員工權利新股之增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4148-2025-08-18-1609-1t5imyx","company_id":"4148","company":"全宇生技-KY","market":"上市","industry":"生技醫療","date":"2025-08-18","time":"16:09:05","subject":"公告本公司114年第2季合併財務報告董事會預計召開日期為114年08月26日","clause":"第31款","fact_date":"2025-08-18","cite_as":"公開資訊觀測站重大訊息：全宇生技-KY（4148），2025-08-18 16:09，「公告本公司114年第2季合併財務報告董事會預計召開日期為114年08月26日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4166-2025-08-18-1539-ahexl4","company_id":"4166","company":"友霖","market":"上櫃","industry":"生技醫療","date":"2025-08-18","time":"15:39:25","subject":"公告本公司股票初次上櫃前現金增資員工認購股款催繳事宜","clause":"第44款","fact_date":"2025-08-18","cite_as":"公開資訊觀測站重大訊息：友霖（4166），2025-08-18 15:39，「公告本公司股票初次上櫃前現金增資員工認購股款催繳事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6491-2025-08-18-1525-rn8mu6","company_id":"6491","company":"晶碩","market":"上市","industry":"生技醫療","date":"2025-08-18","time":"15:25:30","subject":"本公司受邀參加第一金證券舉辦之投資論壇","clause":"第12款","fact_date":"2025-08-21","cite_as":"公開資訊觀測站重大訊息：晶碩（6491），2025-08-18 15:25，「本公司受邀參加第一金證券舉辦之投資論壇」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6733-2025-08-18-1442-1uabrzq","company_id":"6733","company":"博晟生醫","market":"上櫃","industry":"生技醫療","date":"2025-08-18","time":"14:42:46","subject":"本公司接獲通知Revocart獲准取得香港醫療器械許可證","clause":"第53款","fact_date":"2025-08-18","cite_as":"公開資訊觀測站重大訊息：博晟生醫（6733），2025-08-18 14:42，「本公司接獲通知Revocart獲准取得香港醫療器械許可證」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4115-2025-08-18-1419-1vlowid","company_id":"4115","company":"善德生技","market":"興櫃","industry":"生技醫療","date":"2025-08-18","time":"14:19:45","subject":"公告本公司董事解任","clause":"第6款","fact_date":"2025-08-18","cite_as":"公開資訊觀測站重大訊息：善德生技（4115），2025-08-18 14:19，「公告本公司董事解任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6666-2025-08-18-1340-1kggfij","company_id":"6666","company":"羅麗芬-KY","market":"上市","industry":"生技醫療","date":"2025-08-18","time":"13:40:10","subject":"更正資金貸與資訊揭露明細表","clause":"第51款","fact_date":"2025-08-18","cite_as":"公開資訊觀測站重大訊息：羅麗芬-KY（6666），2025-08-18 13:40，「更正資金貸與資訊揭露明細表」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4732-2025-08-18-1140-2k4xpw","company_id":"4732","company":"彥臣","market":"興櫃","industry":"生技醫療","date":"2025-08-18","time":"11:40:41","subject":"代子公司御華生醫公告自主研發新藥NBM-BMX已於114/6/30向美國食品藥物管理局(FDA)提出「轉移性葡萄膜黑色素瘤」之二期人體臨床試驗申請(更正7/15重訊之事實發生日為6/30)","clause":"第8款","fact_date":"2025-06-30","cite_as":"公開資訊觀測站重大訊息：彥臣（4732），2025-08-18 11:40，「代子公司御華生醫公告自主研發新藥NBM-BMX已於114/6/30向美國食品藥物管理局(FDA)提出「轉移性葡萄膜黑色素」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}